Biology of Blood and Marrow Transplantation
Volume 11, Issue 2 , Pages 77-84 , February 2005

Riches usher dilemmas: Antifungal therapy in invasive aspergillosis

  • Pranatharthi Chandrasekar

      Affiliations

    • Department of Internal Medicine, Wayne State University, Detroit, MI
    • Corresponding Author InformationCorrespondence and reprint requests: Pranatharthi Chandrasekar, MD, Harper University Hospital, S Hudson Building, 3990 John R, Detroit, Michigan 48201

Received 3 August 2004 ,Accepted 17 November 2004.

References 

  1. McNeil MM , Nash SL , Hajjeh RA , et al.   Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997 . Clin Infect Dis. . 2001;33:641–647
  2. Baddley JW , Stroud TP , Salzman D , Pappas PG . Invasive mold infections in allogeneic bone marrow transplant recipients . Clin Infect Dis. . 2001;32:1319–1324
  3. Marr KA , Carter RA , Crippa F , Wald A , Corey L . Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients . Clin Infect Dis. . 2002;34:909–917
  4. Denning DW . Invasive aspergillosis in immunocompromised patients . Curr Opin Infect Dis. . 1994;7:456–462
  5. Schaffner A , Douglas H , Braude A . Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes . J Clin Invest. . 1982;69:617–631
  6. Schneemann M , Schaffner A . Host defense mechanism in Aspergillus fumigatus infections . Contrib Microbiol. . 1999;2:57–68
  7. Wingard JR . Antifungal chemoprophylaxis after blood and marrow transplantation . Clin Infect Dis. . 2002;34:1386–1390
  8. Palmer LB , Greenberg HE , Schiff MJ . Corticosteroid treatment as a risk factor for invasive aspergillosis in patients with lung disease . Thorax . 1991;46:15–20
  9. Patterson TF , Kirkpatrick WR , White M , et al.   Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group . Medicine (Baltimore) . 2000;79:250–260
  10. Lin SJ , Schranz J , Teutsch SM . Aspergillosis case-fatality rate (systematic review of the literature) . Clin Infect Dis. . 2001;32:358–366
  11. Bowden R , Chandrasekar P , White MH , et al.   A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients . Clin Infect Dis. . 2002;35:359–366
  12. Ostrosky-Zeichner L , Marr KA , Rex JH , Cohen SH . Amphotericin B (time for a new “gold standard.”) . Clin Infect Dis. . 2003;37:415–425
  13. Mehta J , Kelsey S , Chu P , et al.   Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies . Bone Marrow Transplant. . 1997;20:39–43
  14. Walsh TJ , Hiemenz JW , Seibel NL , et al.   Amphotericin B lipid complex for invasive fungal infections (analysis of safety and efficacy in 556 cases) . Clin Infect Dis. . 1998;26:1383–1396
  15. Mills W , Chopra R , Linch DC , Goldstone AH . Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients (a single-centre experience of 133 episodes in 116 patients) . Br J Haematol. . 1994;86:754–760
  16. Ng TT , Denning DW . Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data . Arch Intern Med. . 1995;155:1093–1098
  17. Timmers GJ , Zweegman S , Simoons-Smit AM , van Loenen AC , Touw D , Huijgens PC . Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients (data of a prematurely stopped clinical trial) . Bone Marrow Transplant. . 2000;25:879–884
  18. Wingard JR , White MH , Anaissie E , Raffalli J , Goodman J , Arrieta A  L Amph/ABLC Collaborative Study Group . A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia . Clin Infect Dis. . 2000;31:1155–1163
  19. Walsh TJ , Goodman JL , Pappas P , et al.   Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi (maximum tolerated dose study) . Antimicrob Agents Chemother. . 2001;45:3487–3496
  20. Herbrecht R , Denning DW , Patterson TF , et al.  Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer  Global Aspergillus Study Group   Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis . N Engl J Med. . 2002;347:408–415
  21. Denning DW , Lee JY , Hostetler JS , et al.   NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis . Am J Med. . 1994;97:135–144
  22. Stevens DA , Lee JY . Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria . Arch Intern Med. . 1997;157:1857–1862
  23. Caillot D , Bassaris H , McGeer A , et al.   Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS . Clin Infect Dis. . 2001;33:83–90
  24. Maertens J , Raad I , Sable C , et al.   Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin, amphotericin B lipid formulations, or azoles . [abstract j-1103] Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto) . Washington, DC: American Society for Microbiology; 2000;
  25. Maertens J , Raad I , Petrikkos G , et al.   Update on the multicenter noncomparative study of caspofungin in adults with invasive aspergillosis refractory or intolerant to other antifungal agents (analysis of 90 patients) . [abstract N-868] Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego) . Washington, DC: American Society for Microbiology; 2002;
  26. Warris A , Weemaes CM , Verweij PE . Multidrug resistance in Aspergillus fumigatus . N Engl J Med. . 2002;347:2173–2174
  27. Marty FM , Cosimi LA , Baden LR . Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants . N Engl J Med. . 2004;350:950–952
  28. Imhof A , Balajee SA , Fredricks DN , Englund JA , Marr KA . Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole . Clin Infect Dis. . 2004;39:743–746
  29. Siwek GT , Dodgson KJ , de Magalhaes-Silverman M , et al.   Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis . Clin Infect Dis. . 2004;39:584–587
  30. Perfect JR , Marr KA , Walsh TJ , et al.   Voriconazole treatment for less-common, emerging, or refractory fungal infections . Clin Infect Dis. . 2003;36:1122–1131
  31. Sutton DA , Sanche SE , Revankar SG , Fothergill AW , Rinaldi MG . In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole . J Clin Microbiol. . 1999;37:2343–2345
  32. Walsh TJ , Petraitis V , Petraitiene R , et al.   Experimental pulmonary aspergillosis due to Aspergillus terreus (pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B) . J Infect Dis. . 2003;188:305–319
  33. Iwen PC , Rupp ME , Langnas AN , Reed EC , Hinrichs SH . Invasive pulmonary aspergillosis due to Aspergillus terreus (12-year experience and review of the literature) . Clin Infect Dis. . 1998;26:1092–1097
  34. Steinbach WJ , Benjamin DK , Kontoyiannis DP , et al.   Infections due to Aspergillus terreus (a multicenter retrospective analysis of 83 cases) . Clin Infect Dis. . 2004;39:192–198
  35. Johnson MD , MacDougall C , Ostrosky-Zeichner L , Perfect JR , Rex JH . Combination antifungal therapy . Antimicrob Agents Chemother. . 2004;48:693–715
  36. Steinbach WJ , Stevens DA , Denning DW . Combination and sequential antifungal therapy for invasive aspergillosis (review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001) . Clin Infect Dis. . 2003;37:S188–S224
  37. Sugar AM . Use of amphotericin B with azole antifungal drugs (what are we doing?) . Antimicrob Agents Chemother. . 1995;39:1907–1912
  38. Denning DW , Hanson LH , Perlman AM , Stevens DA . In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents . Diagn Microbiol Infect Dis. . 1992;15:21–34
  39. Hughes CE , Harris C , Moody JA , Peterson LR , Gerding DN . In vitro activities of amphotericin B in combination with four antifungal agents and rifampin against Aspergillus spp . Antimicrob Agents Chemother. . 1984;25:560–562
  40. Maesaki S , Kohno S , Kaku M , Koga H , Hara K . Effects of antifungal agent combinations administered simultaneously and sequentially against Aspergillus fumigatus . Antimicrob Agents Chemother. . 1994;38:2843–2845
  41. Arikan S , Lozano-Chiu M , Paetznick V , Rex JH . In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp . Antimicrob Agents Chemother. . 2002;46:245–247
  42. Perea S , Gonzalez G , Fothergill AW , Kirkpatrick WR , Rinaldi MG , Patterson TF . In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp . Antimicrob Agents Chemother. . 2002;46:3039–3041
  43. Kirkpatrick WR , Perea S , Coco BJ , Patterson TF . Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis . Antimicrob Agents Chemother. . 2002;46:2564–2568
  44. Petraitis V , Petraitiene R , Sarafandi AA , et al.   Combination therapy in treatment of experimental pulmonary aspergillosis (synergistic interaction between an antifungal triazole and an echinocandin) . J Infect Dis. . 2003;187:1834–1843
  45. Lum LR , Turco TF , Leone J . Combination therapy with caspofungin and amphotericin B lipid complex . Am J Health Syst Pharm. . 2002;59:80–81
  46. Rubin MA , Carroll KC , Cahill BC . Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans . Clin Infect Dis. . 2002;34:1160–1161
  47. Kontoyiannis DP , Hachem R , Lewis RE , et al.   Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies . Cancer . 2003;98:292–299
  48. Aliff TB , Maslak PG , Jurcic JG , et al.   Refractory Aspergillus pneumonia in patients with acute leukemia (successful therapy with combination caspofungin and liposomal amphotericin) . Cancer . 2003;97:1025–1032
  49. Marr KA , Boeckh M , Carter RA , Kim HW , Corey L . Combination antifungal therapy for invasive aspergillosis . Clin Infect Dis. . 2004;39:797–802
  50. Maertens J , Van Eldere J , Verhaegen J , Verbeken E , Verschakelen J , Boogaerts M . Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients . J Infect Dis. . 2002;186:1297–1306
  51. Maertens J , Verhaegen J , Lagrou K , Van Eldere J , Boogaerts M . Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients (a prospective validation) . Blood . 2001;97:1604–1610
  52. Mennink-Kersten MA , Donnelly JP , Verweij PE . Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis . Lancet Infect Dis. . 2004;4:349–357
  53. Adam O , Auperin A , Wilquin F , Bourhis JH , Gachot B , Chachaty E . Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies . Clin Infect Dis. . 2004;38:917–920
  54. Boutboul F , Alberti C , Leblanc T , et al.   Invasive aspergillosis in allogeneic stem cell transplant recipients (increasing antigenemia is associated with progressive disease) . Clin Infect Dis. . 2002;34:939–943
  55. Kawazu M , Kanda Y , Nannya Y , et al.   Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1→3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders . J Clin Microbiol. . 2004;42:2733–2741
  56. Buchheidt D , Hummel M , Schleiermacher D , Spiess B , Hehlmann R . Current molecular diagnostic approaches to systemic infections with aspergillus species in patients with hematological malignancies . Leuk Lymphoma. . 2004;45:463–468
  57. Denning DW , Ribaud P , Milpied N , et al.   Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis . Clin Infect Dis. . 2002;34:563–571
  58. Winston DJ , Maziarz RT , Chandrasekar PH , et al.   Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients (A multicenter, randomized trial) . Ann Intern Med. . 2003;138:705–713
  59. Masia Canuto M , Gutierrez Rodero F . Antifungal drug resistance to azoles and polyenes . Lancet Infect Dis. . 2002;2:550–563
  60. Loeffler J , Stevens DA . Antifungal drug resistance . Clin Infect Dis. . 2003;36:S31–S41
  61. Chandrasekar PH , Cutright JL , Manavathu EK . Correlation of in vitro and in vivo susceptibilities of laboratory-selected amphotericin B-resistant isolates of Aspergillus fumigatus . Programs and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September . 2002;
  62. Dannaoui E , Borel E , Monier MF , Piens MA , Picot S , Persat F . Acquired itraconazole resistance in Aspergillus fumigatus . J Antimicrob Chemother. . 2001;47:333–340
  63. Denning DW , Radford SA , Oakley KL , Hall L , Johnson EM , Warnock DW . Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection . J Antimicrob Chemother. . 1997;40:401–414
  64. Moore CB , Sayers N , Mosquera J , Slaven J , Denning DW . Antifungal drug resistance in Aspergillus . J Infect. . 2000;41:203–220
  65. Warris A , Weemaes CM , Verweij PE . Multidrug resistance in Aspergillus fumigatus . N Engl J Med. . 2002;347:2173–2174
  66. Manavathu E , Espinel-Ingroff A , Alangaden G , Chandrasekar P . Molecular studies on voriconazole-resistance in a clinical isolate of Aspergillus fumigatus . Programs and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September . 2003;
  67. Balajee SA , Weaver M , Imhof A , Gribskov J , Marr KA . Aspergillus fumigatus variant with decreased susceptibility to multiple antifungals . Antimicrob Agents Chemother. . 2004;48:1197–1203
  68. Kontoyiannis DP , Lewis RE , Sagar N , May G , Prince RA , Rolston KV . Itraconazole-amphotericin B antagonism in Aspergillus fumigatus (an E-test-based strategy) . Antimicrob Agents Chemother. . 2000;44:2915–2918
  69. Ratanatharathorn R , Flynn P , VanBurik J , et al.   Micafungin in combination with systemic antifungal agents in the treatment of refractory aspergillosis in bone marrow transplant patients . Abstracts of the 44th Annual Meeting of the American Society of Hematology, Philadelphia, PA, December . 2002;
  70. Hooshmand-Raad R , Reed M , Chu A , et al.   Safety of high dose/long duration amphotericin B lipid complex therapy. Focus on fungal infections 14, New Orleans, LA, March . 2004;
  71. Denning DW , Marinus A , Cohen J , et al.  EORTC Invasive Fungal Infections Cooperative Group   An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients (diagnosis and therapeutic outcome) . J Infect. . 1998;37:173–180
  72. Caillot D , Couaillier JF , Bernard A , et al.   Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia . J Clin Oncol. . 2001;19:253–259
  73. Cordonnier C , Maury S , Pautas C , et al.   Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients . Bone Marrow Transplant. . 2004;33:943–948
  74. Cordonnier C , Beaune J , Offner F , Marinus A , Ljungman P , Meunier F  Infectious Diseases Working Party of the EBMT and the EORTC Invasive Fungal Infections Cooperative Group . Aspergillosis prior to bone marrow transplantation . Bone Marrow Transplant. . 1995;16:323–324
  75. Offner F , Cordonnier C , Ljungman P , et al.   Impact of previous aspergillosis on the outcome of bone marrow transplantation . Clin Infect Dis. . 1998;26:1098–1103

PII: S1083-8791(04)00624-X

doi: 10.1016/j.bbmt.2004.11.021

Biology of Blood and Marrow Transplantation
Volume 11, Issue 2 , Pages 77-84 , February 2005

Article Tools